Patents by Inventor Heidi Yoder
Heidi Yoder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140220027Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder Pixley, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20130071379Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: March 21, 2013Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20120301461Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: May 8, 2012Publication date: November 29, 2012Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peizhi (Peter) Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Patent number: 8188233Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: February 6, 2009Date of Patent: May 29, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Patent number: 8188234Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: GrantFiled: February 6, 2009Date of Patent: May 29, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20090246192Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: February 6, 2009Publication date: October 1, 2009Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Laura Orsatti, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li
-
Publication number: 20090232795Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.Type: ApplicationFiled: February 6, 2009Publication date: September 17, 2009Inventors: Jon H. Condra, Rose M. Cubbon, Holly A. Hammond, Timothy McCabe, Shilpa Pandit, Laurence B. Peterson, Joseph C. Santoro, Ayesha Sitlani, Dana D. Wood, Henryk Mach, Heidi Yoder, Sonia M. Gregory, Jeffrey T. Blue, Kevin Wang, Peter Luo, Denise K. Nawrocki, Pingyu Zhong, Feng Dong, Yan Li